introduction
In general, ovarian cancer is often diagnosed at advanced stages due to late symptom presentation and thus has a poor prognosis [1] . Epithelial ovarian cancer has recently been proposed to be subdivided into two types. Low-grade type I cancers arise from borderline tumors and are often limited to the ovaries at time of diagnosis and show mutations of RAS, BRAF and PTEN. In contrast, type II carcinomas are frequently deficient in the p53 pathway, are more aggressive and thus often widely spread through the peritoneal cavity at time of diagnosis [2, 3] . Classic treatment of both types is based on primary debulking surgery followed by chemotherapy. Although more than half of these patients achieve complete remission after initial surgical debulking and primary platinum-based chemotherapy, overall 5-year survival remains unacceptably poor at <40% [4] . The major obstacle to a better clinical outcome in ovarian cancer is the rapid development of resistance to platinum during treatment and indeed, up to 75% of initial platinum responders relapse within the first 2 years [5] . In addition, 25% of the carcinomas of the ovary are either primarily refractory to platinum compounds or relapse within 6 months after first-line treatment and are thus considered platinum resistant [1] . Therefore, there is an urgent need for a better understanding of the molecular background involved in the mechanisms causing platinum resistance and to outline biomarkers allowing an early identification of patients at high risk for platinum-resistant relapse.
L1-cell adhesion molecule (L1CAM) is a 200-to 220-kDa transmembrane protein that belongs to the immunoglobulin superfamily [6] . It was initially identified on neuronal cells and is involved in axon outgrowth and guidance during central nervous system development [7] [8] [9] . L1CAM expression has been reported for various tumor entities, where it correlates with advanced-stage disease and metastasis [10, 11] . L1CAM is highly expressed in ovarian and endometrial carcinomas [12] [13] [14] [15] . The extracellular part of the full-length L1CAM is subject to membrane-proximal cleavage, which generates a soluble form of ∼200-kDa soluble L1CAM (sL1CAM) [16] [17] [18] . L1CAM cleavage and release of the soluble molecule has been shown to promote migration, invasion and protection from apoptosis of cancer cells in vitro [18, 19] . Soluble L1CAM can be detected in serum and ascitic fluid of ovarian and endometrial carcinoma patients [12] . The prognostic significance of soluble versus membrane-bound L1CAM in serous ovarian cancer has not been investigated yet.
Increasing evidence suggests that inflammation is a major driving force for tumor progression [20, 21] . Attracted immune cells, stroma and tumor cells interacting with each other produce a pro-inflammatory milieu that is beneficial for tumor growth [20, 22] . Cytokines released into the tumor microenvironment activate multiple signaling pathways, among them the nuclear factor 'kappa-light-chain-enhancer' of activated B cells (NF-κB) and the signal transducer and activator of transcription 3 pathway, that favor tumor progression [23] . Activation of these pathways support cell proliferation, migration, invasive growth and chemoresistance through up-regulation of antiapoptotic genes [20] . The expression of classical NF-κB pathway effectors in human ovarian cancer has been reported [24] . The cytokine interleukin-1 beta (IL-1β), a prototype activator of the noncanonical NF-κB pathway, is secreted by stroma and immune cells as well as cancer cells [22, 25] . Two recent publications have provided evidence that L1CAM can induce NF-κB activation, promoting cell proliferation in vitro and metastasis formation in vivo [26, 27] . We recently reported that, in pancreatic ductal adenocarcinoma (PDAC), L1CAM expression induces the production of IL-1β leading to autocrine/paracrine activation of the IL-1 receptor [28] .
In the present report, we have investigated the functional role of L1CAM in ovarian carcinoma progression and prognosis and, in analogy to PDAC, we analyzed a putative role of L1CAM on IL-1β expression and NF-κB activation in ovarian carcinoma cell lines.
patients and methods definition of recurrence and response to treatment
Response to treatment and diagnosis of recurrence was determined according to RECIST and/or Rustin criteria [29, 30] . Patients with recurrence during primary therapy or within 6 months after primary therapy were defined as nonresponders.
Methods for sample preparation, in vitro experiments and statistical analysis are listed in supplemental Text 1 (available at Annals of Oncology online).
results

L1CAM expression and shedding in serous ovarian cancers
Data and samples from 270 ovarian cancer patients who underwent surgery followed by carboplatin-paclitaxel chemotherapy were collected. In the present study, we restricted our analysis to the 232 ovarian cancers with serous Table 1 .
From the whole patient collective, 192 tumor lysates and the supernatant of 176 ascites samples were collected before the start of chemotherapy. When applied to tumor lysate, the enzyme-linked immunosorbent assay (ELISA) quantifies the content of full-length membrane-bound L1CAM (mL1CAM) in the tumor samples, whereas in ascitic fluid the content of soluble shed L1CAM (sL1CAM) is detected. As the L1CAM and IL-1β measurements were highly skewed ( Figure 1A , Figure 1B and Figure 1D ), we carried out a log transformation with an offset of 0.1 ( Figure 1C and Figure 1D ). We found a significant increase of mL1CAM levels in the tumor lysate from FIGO II to FIGO III/IV (P = 0.005). As expected, we observed a correlation of mL1CAM in tumor lysates and sL1CAM levels in the ascitic fluid, respectively [r s = 0.39; 95% confidence interval (CI) 0.24-0.53; P < 0.0001]. This suggested that the shedding of L1CAM is primarily a function of L1CAM expression in serous ovarian cancer.
membraneous L1CAM predicts tumor resectability and lymphogenic spread As mL1CAM is known to mediate migration and invasion in vitro, we tested the correlation with incomplete primary debulking surgery and metastasis. We found a significant correlation between mL1CAM expression levels and the risk for incomplete debulking in univariate (odds ratio = 2.2; 95% CI 1.31-3.69; P = 0.0014) (Figure 2A ) and multivariate analysis (Table 2 ). Furthermore, mL1CAM was found to be significantly higher in patients with lymphogen metastases (odds ratio = 2.37; 95% CI 1.38-4.06; P = 0.0008; Figure 2B ) and could be identified as a new independent marker for lymphogenic spread in multivariate analysis ( Table 2) .
We analyzed p53 functionality in the ovarian cancer samples to categorize them according to a type I-and II-like phenotype. We found elevated mL1CAM levels in tumor lysates with impaired p53 activity ( Figure 2C ).
prognostic value of soluble L1CAM
As sL1CAM was shown to be involved in chemoresistance [19] , we evaluated its role as a marker for progression-free survival (PFS), overall survival (OS) and chemoresistance. Patients with lower sL1CAM showed significantly prolonged PFS (P < 0.0001) and a trend toward prolonged OS (P = 0.06), when analyzing sL1CAM as continuous marker. As L1CAM is expressed on neurons and to a minor rate on other cell types of the human body [31] , sL1CAM can be detected in body fluids in healthy individuals. Thus, in order to define clinical risk groups, sL1CAM was dichotomized into high-risk/low-risk group as described in the statistical methods. For PFS, we found a cut-off value of 5.4 ng/ml for sL1CAM, which proved to be significant in univariate (P = 0.0004) and multivariate analysis ( Table 2) . Patients with sL1CAM levels <5.4 ng/ml had a 2-year PFS rate of 53%, whereas patients with measurements above the cut-off had only 24% ( Figure 3A) . Analysis of sL1CAM and its effects on OS revealed a tendency toward shortened OS in patients with sL1CAM >5.4 ng/ml (hazard ratio = 1.86; 95% CI 0.82-4.24; P = 0.1371) and for mL1CAM when analyzed as a continuous marker (hazard ratio = 1.48; 95% CI 1-2.21; P = 0.0429) but did not prove to be significant in multivariate analysis (supplemental Table S1 , available at Annals of Oncology online).
We found a correlation between sL1CAM in ascitic fluid and poor response to chemotherapy ( Figure 3B ). Applying a cut-off value of 5.4 ng/ml, we were able to define a group with a high risk for chemoresistance (P = 0.0271). The high-risk group (n = 114) above the cut-off had a rate of 31.6% chemoresistance, whereas the low-risk group (n = 61) beared a risk of 11.5%. 
presence of IL-1β in tumor lysate
IL-1β is a gatekeeper of inflammation and has been implicated to play a role in the initiation and development of epithelial ovarian cancer [25] . We therefore determined IL-1β levels in tumor lysates by ELISA ( Figure 1D ). We found IL-1β to be abundantly detectable in the ovarian cancer samples (mean value 37.7 pg/ml lysate; range 0-465 pg/ml). However, we were unable to reveal a correlation between the amount of IL-1β in the lysate and the L1CAM status.
role of L1CAM for IL-1β production and NF-κB activity
To further investigate a possible link between L1CAM and IL-1β expression in tumor cells, we used the established cells lines HTB77 and OVCAR3 that expressed L1CAM at the cell surface and secreted sL1CAM into the medium ( Figure 4A and Figure 4B ). Both cell lines expressed detectable levels of IL-1 receptor at the cell surface ( Figure 4C ) and upon stimulation with IL-1β responded with greatly enhanced NF-κB activation as measured by a phospho-specific NF-κB ELISA ( Figure 4D ). Both cell lines also expressed IL-1β messenger RNA (mRNA) and secreted IL-1β into the medium ( Figure 5A ). We next examined whether L1CAM contributed to IL-1β expression using short interfering RNA-mediated knock-down of L1CAM. The specific knock-down was verified by quantitative RT-PCR and by western blot analysis ( Figure 5B ). The analysis after L1CAM knock-down revealed a significant reduction of IL-1β mRNA ( Figure 5C ) and NF-κB activity (Figure 5d ). These results suggested that L1CAM expression in ovarian carcinoma cell lines can augment IL-1β expression and contribute to NF-κB activation in an autocrine/paracrine manner. discussion L1CAM has been recognized to play an important role in human tumor progression. In a previous study, largely based on immunohistochemistry (IHC), we reported that L1CAM expression is a marker for unfavorable prognosis in ovarian carcinoma [12] . However, IHC is not a quantitative procedure and cannot assess the prognostic role of sL1CAM that is released from the tumor and can be detected in the blood and ascitic fluid of ovarian carcinoma patients [12] . In the present report, we have specifically concentrated on the examination of 232 serous ovarian carcinomas and have addressed this problem by using a quantitative ELISA for the detection of mL1CAM from tumor lysate and sL1CAM in ascitic fluid. We observed the following: (i) mL1CAM expression levels significantly correlated with the risk for incomplete debulking.
(ii) mL1CAM levels were significantly higher in cancers with deficient p53 activity (type II like). The p53 yeast assay revealed that most of the included cancers exhibited impaired p53 pathway and thus belong to the high-grade type II-like serous ovarian cancers. Although we consider this result with caution due to the uneven distribution of subgroups, we were none the less able to demonstrate statistical significance. (iii) We ascertain that sL1CAM is an independent prognostic marker for PFS. High levels of sL1CAM were associated with poor response to chemotherapy. (iv) We detected IL-1β in tumor lysates and in established ovarian carcinoma cell lines in which it was dependent on L1CAM. Our results suggest a link between L1CAM and NF-κB activation via IL-1β that could be instrumental for the progression of ovarian carcinoma. Phospho-NF-κB was determined via a specific ELISA. Data are pooled from five independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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Earlier findings have shown that the ectopic L1CAM expression in mouse or human cell lines strongly augmented the invasion into matrigel as well as haptotactic cell migration [18, 32, 33] . Likewise, specific knock-down of L1CAM or anti-L1CAM antibodies could block invasion and cell motility [34] [35] [36] [37] . Here, we present evidence that mL1CAM expression was correlated with the risk for incomplete debulking. In ovarian cancer, the normal peritoneal surface, lining both the abdominal cavity and the viscera, is generally considered as a natural barrier for deeper cancer invasion and therefore may facilitate resection of disseminated tumor plaques. Despite a constantly increasing surgical radicality in ovarian cancer and improved technical skills of the gynecologic oncology surgeons, there are a number of patients where a complete surgical clearance of the tumor none the less remains impossible. These tumors are probably characterized by a much higher invasive potential than others, and with regard to surgical resectability may sometimes behave similar to malignant mesenchymal tumors, where complete resection generally is very arduous. This is in line with the recent findings showing that expression of L1CAM is considerably increased during epithelial mesenchymal transition and detected in the invading edge of cancers by IHC in endometrial or ovarian cancers [14, 15] . We conclude that L1CAM is a reliable marker to distinguish cancers with a highly invasive phenotype and thereby explains the different outcomes of debulking surgeries in the individual cases of ovarian cancers. We think that employing sL1CAM as a prognostic marker is a good alternative to IHC as sample acquisition is easy and mild for the patient compared with laparoscopy. A further advantage is the relative cheap and easy measurement of L1CAM via ELISA.
A small fraction of L1CAM can undergo ectodomain shedding involving the metalloproteinases ADAM10 and ADAM17 [18, 38, 39] . It has been difficult to dissect the functional roles of mL1CAM versus sL1CAM in ovarian cancer. sL1CAM contains the amino acid sequence Arg-GlyAsp (RGD motif ) in the sixth immunoglobulin-like domain that supports α5-and αv-integrin-mediated cell binding [40] . sL1CAM can trigger cell motility [18] and has pro-angiogenic activity in the chicken chorioallantoic membrane assay when offered in solution [41] . sL1CAM has been detected in ovarian and endometrial carcinoma patients [12] and in the cerebrospinal fluid of patients with Alzheimer's disease and other dementia syndromes [42] . A recent study has shown that circulating levels of sL1CAM in the blood of gastrointestinal stromal tumor patients can be used as a prognostic marker [43] . From a diagnostic point of view, it would be more practical to determine sL1CAM in the serum of ovarian carcinoma patients. Although we investigated serum samples from our patients, we were unable to detect any correlation between sL1CAM levels in serum and clinicopathological parameters or L1CAM measurements from tumor lysate or ascitic fluid.
The immobilized L1CAM ectodomain (either native or in recombinant fragments) promotes cell adhesion [18, 40] and triggers NF-κB activation via integrins [44] . In addition, sL1CAM from ascites of ovarian carcinoma patients can induce extracellular signal-regulated kinase phosphorylation [45] . Previous work has shown that L1CAM augments protection from apoptosis in PDAC [46] . In the present report, we have shown for the first time that sL1CAM in the ascites is an independent prognostic marker for PFS and correlates with poor response to first-line chemotherapy. The induction of chemoresistance by adding sL1CAM to medium of ovarian cancer cells has already been described and seems to involve integrin signaling as FAK phosphorylation has been observed [19] . Collectively, these findings suggest that L1CAM ectodomain cleavage can give rise to the activation of multiple antiapoptotic signaling pathways to allow cell survival.
We recently found that mL1CAM binding to integrins on adjacent tumor cells can trigger the expression and release of IL-1β [26] . We therefore determined the level of IL-1β in the tumor lysate of ovarian carcinoma patients. Although the cytokine was detected in most of the lysates, there was correlation with neither L1CAM expression as determined by ELISA nor with mRNA expression levels as determined by Affimetrix DNA chip analysis (D. Pils, unpublished data). As IL-1β is expressed and secreted by multiple cells, i.e. stroma cells, infiltrated immune cells as well as tumor cells, it may not necessarily correlate with L1CAM expressed on tumor cells.
The results obtained from our in vitro experiments suggest that the knock-down of L1CAM reduced the amount of IL-1β and diminished NF-κB activity. These observations provide the first evidence for a meaningful role of L1CAM in constitutive NF-κB activation in ovarian cancer. Further studies will be necessary to examine the role of L1CAM expression and NF-κB activation in the invasiveness and metastatic spread of ovarian cancer. The clinical material and data collected in the framework of the OVCAD consortium will be of great help for these ongoing studies.
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